報價延遲最少15分鐘:2025/05/31 16:06 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
572.87 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
16.40/14.37
|
|
企業價值
35.51B
|
| 資產負債 |
|
每股賬面淨值
90.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
36.42M
|
|
每股收益
16.27
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 16:06 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease. |